1	Antibodies to Aedes aegypti D7L salivary proteins as a new
2	serological tool to estimate human exposure to Aedes mosquitoes.
3	
4	Sophana Chea ^{1†} , Laura Willen ^{2†} , Sreynik Nhek ¹ , Piseth Ly ¹ , Kristina Tang ² , James
5	Oristian ² , Roberto Salas-Carrillo ² , Aiyana Ponce ² , Paola Carolina Valenzuela Leon ² ,
6	Dara Kong ¹ , Sokna Ly ² , Ratanak Sath ² , Chanthap Lon ^{1,2} , Rithea Leang ^{3,4} , Rekol
7	Huy ³ , Christina Yek ^{1,2} , Jesus G. Valenzuela ² , Eric Calvo ² , Jessica E. Manning ^{1,2} ,
8	Fabiano Oliveira ^{1,2*} .
9	
10	¹ International Center of Excellence in Research, National Institute of Allergy and
11	Infectious Diseases, Phnom Penh, Cambodia
12	² Laboratory of Malaria and Vector Research, National Institute of Allergy and
13	Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
14	³ National Center for Parasitology, Entomology, and Malaria Control, Ministry of
15	Health, Phnom Penh, Cambodia
16	⁴ National Dengue Control Program, Ministry of Health, Phnom Penh, Cambodia
17	
18	
19	Sophana Chea ^{1†} and Laura Willen ^{2†} : These authors contributed equally to this work
20	and share first authorship.
21	
22	
23	* Correspondence: Fabiano Oliveira, loliveira@nih.gov
24	
25	
26	Keywords: Aedes; Aedes aegypti; exposure marker, ELISA, dengue, biomarker,
27	Cambodia; mosquito saliva.
28	
29	
30	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 **1 Abstract**

32

Introduction: Aedes spp. are the most prolific mosquito vectors in the world. Found 33 34 on every continent, they can effectively transmit various arboviruses, including the dengue virus which continues to cause outbreaks worldwide and is spreading into 35 previously non-endemic areas. The lack of widely available dengue vaccines 36 accentuates the importance of targeted vector control strategies to reduce the 37 dengue burden. High-throughput sensitive tools to estimate human-mosquito contact 38 and evaluate vector control interventions are lacking. We propose a novel serological 39 tool that allows rapid screening of large human cohorts for exposure to potentially 40 infectious mosquitoes and effective targeting of vector control. 41 **Methods:** We tested 563 serum samples from a longitudinal pediatric cohort study 42 previously conducted in Cambodia. Children enrolled in the study were dengue-43 naïve at baseline and were followed biannually for dengue incidence for two years. 44 We used Western blotting and enzyme-linked immunosorbent assays to identify the 45 most immunogenic Aedes aegypti salivary proteins and measure total anti-Ae. 46 Aegypti IgG. 47 **Results**: We found a strong correlation (r_s=0.86) between the combined IgG 48 responses against AeD7L1 and AeD7L2 recombinant proteins and those to whole 49 salivary gland homogenate. We observed seasonal fluctuations of AeD7L1+2 IgG 50 responses, corresponding to Aedes spp. abundance in the region, and no cross-51 reactivity with Culex guinguefasciatus and Anopheles dirus mosquitoes. The 52 53 baseline median AeD7L1+2 IgG responses for young children were higher in those who developed asymptomatic dengue versus those who developed symptomatic 54 dengue. 55 **Conclusion:** The IgG response against AeD7L1+2 recombinant proteins is a highly 56 sensitive and Aedes specific marker of human exposure to Aedes bites that can 57 facilitate standardization of future serosurveys and epidemiological studies by its 58 ability to provide a robust estimation of human-mosquito contact in a high-throughput 59

60 fashion.

All rights reserved. No reuse allowed without permission.

61 2 Introduction

62

Dengue is the most prevalent arboviral disease worldwide, with the greatest burden
in tropical and sub-tropical regions (1, 2). Half the world's population is at risk of
contracting dengue, including 1.3 billion people living in ten dengue-endemic
countries of the South-East Asian region (3). From 2015 to 2019, dengue cases in
the region increased by 46% culminating in a major epidemic in 2019 that led to the
highest number of annual global cases (>5.2 million) ever to be reported in the same
year (4).

70 Currently, existing vaccines remain selectively available; thus, prevention and control

of dengue heavily rely on effective vector control measures targeted towards *Aedes*

mosquitoes. The efficacy of these vector control methods is currently evaluated

vsing expensive and labor-intensive insect trapping that may not reflect true human

exposure to mosquito bites. An alternative approach exploits the human humoral

immune responses against the vector's salivary components that are injected during

a bloodmeal. Salivary proteins of several hematophagous arthropods were

previously identified and shown to facilitate blood feeding by limiting the host's

vasoconstriction, inhibiting coagulation processes, and suppressing pain receptors

79 (5). Saliva of *Aedes aegypti* female mosquitoes contains about 100 abundant

salivary proteins (6, 7) that are implicated in enhanced viral dissemination and

81 increased pathogenesis of viral infections (8).

82 IgG responses against whole salivary gland homogenate of *Aedes* mosquitoes

83 (SGH) correlate with the intensity of mosquito bite exposure (9), and were previously

proposed as a marker of human exposure to *Aedes* mosquitoes (10-12). Since then,

researchers established a repertoire of promising recombinant salivary antigens to

⁸⁶ bypass the potential cross-reactivity of SGH with other vector species and to

87 facilitate the use of biomarkers of *Aedes* exposure in large-scale cohort studies (13),

88 with the Nterm-34kDa peptide biomarker being the most studied (13, 14).

89 Interestingly, none of these studies assessed how well the antibody (Ab) responses

90 against Ae. aegypti recombinant proteins correlate with those against whole saliva or

91 SGH, the reference standard for Aedes exposure. Ab responses against whole SGH

92 and several recombinant Ae. aegypti salivary proteins have also been implicated in

93 associations with disease outcome(15, 16). IgG reactivity to Ae. aegypti salivary

proteins were higher in DENV positive patients than in uninfected patients (9, 15, 94 17). Conversely, Ab responses against the Ae. aegypti D7 proteins, involved in the 95 scavenging of biogenic amines and cysteinyl leukotrienes and, thus, potentially 96 involved in preventing the host's inflammatory response, were higher in DENV 97 positive and febrile patients as opposed to non-febrile patients. In the present study, 98 we identified salivary biomarkers of Ae. aegypti exposure that can replace the use of 99 mosquito saliva or SGH and subsequently investigate if a relationship exists between 100 these surrogate biomarkers of exposure and clinical outcomes in dengue infected 101 102 patients in a longitudinal pediatric cohort in Cambodia (18).

- 103
- 104

105 **3 Results**

106

3.1 Identification of immunogenic Aedes aegypti salivary proteins in a Cambodian pediatric population.

109

We used Western blot to measure the recognition of *Ae. aegypti* salivary proteins by 110 IgG present in the serum of our study population. We observed sera reactivity in the 111 Ae. aegypti SGH molecular weight range of 28 kDa to 98 kDa (Fig 1A). Cambodian 112 sera reactivity increased on par with anti-SGH ELISA OD values (Fig. 1A, 113 Supplementary Fig. 1). Using a digital detection system, we identified reactive 114 protein bands with approximate molecular weights of 80 kDa, 62 kDa, 35 kDa and 30 115 kDa and accounting for 72 %, 88 %, 85 %, and 82 % of the total seropositivity, 116 117 respectively. We next produced and screened 18 Ae. aegypti recombinant salivary proteins by Western blot using a pool of Ae. aegypti SGH reactive sera from our 118 cohort (n=10) (Fig. 1C). We identified five of the 18 Ae. aegypti recombinant salivary 119 proteins as reactive, corresponding to AeApyrase, AeD7L1, AeD7L2, NIH-23, and 120 NIH-27 (Table 1, Supplementary Fig. 2). We scaled up production of these five Ae. 121 aegypti salivary recombinant proteins, verified their purity by Coomassie G-250 122 staining (Fig. 1B) and tested their reactivity to the pooled sera (Fig. 1C). Importantly, 123 sera from healthy U.S. blood donors who were non-reactive on an Ae. aegypti SGH 124 125 ELISA, also did not react to any of the tested recombinant proteins (Fig. 1C).

All rights reserved. No reuse allowed without permission.



- 126
- 127 Figure 1. Sera from children living in dengue-endemic areas in Kampong Speu

128 province, Cambodia recognize native SGH from *Ae. aegypti*. (A) Western blot displaying

- reactivity of Cambodian sera samples organized by increasing *Ae. aegypti* SGH ELISA OD
- 130 values. (B) Coomassie blue stained SDS-PAGE of the five selected recombinant proteins
- 131 (AeD7L2, AeD7L1, NIH-27, NIH-23, and AeApyrase). (C) Western blot with AeD7L2,
- AeD7L1, NIH-27, NIH-23, and AeApyrase against a pool of negative (left) and positive (right)
- 133 sera.
- 134
- 135

	Protein name	Molecular weight (kda)	Accession number	Sera reactivity	Annotation
1	NIH435-36	20.05	ABF18174	No	Putative 14.5 kDa salivary protein (19)
2	NIH435-8	20.6	AAL76029	No	Putative C-type lectin (20)
3	NIH435-4	21	ABF18046	No	Proline rich salivary secreted peptide (19)
4	NIH435-29	21.16	AAL76036	No	Putative 18.2 kDa secreted protein (20)
5	AeD7S	21.25	ABF18082	No	Putative odorant binding protein (19)
6	Aegyptin	30	CAX36783	No	Binds collagen and inhibits platelet aggregation and adhesion (21)
7	NIH435-32	36.4	ABF18025	No	Angiopoietin-like protein variant, Fibrinogen- related domains (FReDs) (19)
8	NIH435-27	36.7	AAL76019	Yes	Putative sticky protein, Angiopoietin related protein, Fibrinogen-related domains (20)
9	AeD7L1	37	AAL16049	Yes	Binds biogenic amines and eicosanoids (22)
10	AeD7L2	37	AAA29347	Yes	Binds biogenic amines and eicosanoids (22)
11	NIH435-31	38.72	ABF18017	No	Putative 34 kDa family secreted salivary protein (19)
12	NIH435-24	39.13	XP_001657055	No	Uncharacterized protein (23)
13	NIH435-16	20.05	XP_001651977	No	Probable uridine nucleosidase 1, Nucleoside hydrolases (23)
14	NIH435-23	20.6	XP_001656512	Yes	Serine protease inhibitors (Serpin) family, clotting inhibitor (24, 25)
15	NIH435-19	21	EAT46066	No	Serine protease inhibitors (Serpin) family, clotting inhibitor (24)
16	NIH435-6	21.16	ABF18028	No	Salivary anti FXa serpin (19)
17	NIH435-21	21.25	XP_001663083	No	Cysteine-rich secretory proteins, antigen 5, pathogenesis-related 1 proteins (23)
18	AeApyrase	61.36	AAC37218.1	Yes	Inhibiting ADP-dependent platelet aggregation (26)

136

Table 1. Name, molecular weight, accession number, serum reactivity, and function of the 137

17 recombinant proteins used for the immunoreactivity screening against Ae. aegypti 138

139 salivary gland homogenate.

140

All rights reserved. No reuse allowed without permission.

141

3.2 The combined antibody responses against *Aedes aegypti* D7L1 and D7L2 salivary proteins is a valid surrogate for antibodies against *Ae. aegypti* SGH.

145

We tested a random subset of 18 Cambodian children sampled at seven consecutive 146 visits during the dry and wet seasons from 2018 to 2021 on an ELISA assay for Abs 147 against the selected recombinant proteins or against SGH (Fig. 2A). We achieved a 148 high correlation between SGH and AeD7L1+2 (r = 0.91, $r_s = 0.92$), AeD7L1 (r = 0.82, 149 $r_s = 0.82$), and AeD7L2 (r = 0.76, $r_s = 0.82$), alone or when combined with 150 AeApyrase, AeNIH-27 or AeNIH-23 (Fig. 2). No significant correlation was observed 151 between Abs against SGH and a negative control antigen (Bovine Serum Albumin, 152 BSA) (r = 0.17 (P = 0.05), r_s = 0.15 (P = 0.1)). We selected the combination of 153 AeD7L1+2 as the optimal and most parsimonious candidate for further analyses. All 154 P values and confidence intervals are displayed in Supplementary Table 1. 155 156 157



158

- 159 Figure 2. Heat map showing the Pearson (A) and Spearman (B) correlation coefficients (r
- and r_s , respectively) between antibody responses against SGH and against AeD7L1+2,
- AeD7L1, or AeD7L2, alone or when combined with AeApyrase, AeNIH-27 or AeNIH-23.
- 162

All rights reserved. No reuse allowed without permission.

3.3 Antibody responses show a seasonal fluctuation that is most pronounced for AeD7L1 and AeD7L1+2.

165

Wet and dry seasons in Cambodia reflect the seasonal abundance of Aedes spp. 166 We detected significant differences in anti-SGH, anti-AeD7L1, anti-AeD7L2, and 167 anti-AeD7L1+2 IgG levels between wet and dry seasons for the same subset of 18 168 Cambodian children who were sampled at seven consecutive visits (Fig. 3). More so, 169 the seasonal fluctuation for AeD7L1 and the composite marker AeD7L1+L2 was 170 stronger (moderate effect size, Kendall W = 0.33 and 0.30, respectively) than that for 171 SGH or AeD7L2 (small effect size, Kendall W=0.17 and 0.19, respectively). No 172 significant differences were observed for the Ab responses against BSA during the 173 wet and dry seasons (Supplementary Fig. 3). 174

175





Figure 3. Seasonal variation in anti-Ae. aegypti IgG levels. Dot and boxplots of
 standardized ELISA optical density (OD) values of 18 individuals tested at seven different

time points (Visit 1 to 7) for IgG against (A) SGH, (B) AeD7L1+2, (C) AeD7L1, and (D)

All rights reserved. No reuse allowed without permission.

AeD7L2. Visit 1, 3, 5, and 7 took place in wet seasons from 2018 to 2021, the other visits took place during the dry seasons. The solid black horizontal line within the boxplots is the median; the lower and upper borders are, respectively, the 1st and 3rd quartiles; the vertical bars indicate the minimum and maximum values. The orange smoothed fitted curves represent a loess regression (span $\alpha = 0.45$) with 95% confidence intervals (shaded area). Results of the overall Friedman rank test are provided.

186

3.4 Children who developed asymptomatic dengue had higher anti AeD7L1+2 antibody titers at baseline than those who developed symptomatic dengue.

190

Sera samples of all children naïve at baseline (n=563) were tested for the response 191 against AeD7L1+2 to assess associations with disease outcome (i.e., no dengue 192 193 infection, asymptomatic dengue, and symptomatic dengue). Correlation coefficients between Ae. aegypti SGH and the AeD7L1+2 recombinant proteins remained strong 194 195 for the full cohort (r=0.85, r_s=0.86). To investigate associations with anti-Aedes Ab levels at baseline and disease, we first fitted Cox PH models that consider time to 196 197 any dengue infection. We did not observe any significant differential risk for dengue between children with high or low baseline Ab levels, for neither SGH, nor AeD7L1+2 198 (Supplementary Table 2 and 3). We then tested the distribution of baseline Ab 199 responses to SGH and AeD7L1+2 with age and disease outcome group. Accounting 200 for age, disease outcome, and an age x disease outcome interaction term, 201 multivariate models revealed that overall Ab responses decreased with increasing 202 age for both SGH and D7L1+2 (Fig. 4A). However, the Ab response of children who 203 developed symptomatic dengue increased with age compared to children who 204 developed asymptomatic dengue (test of age × disease outcome interaction 205 term (Fig. 4A). Marginal effect plots of the age x disease outcome interaction from 206 the GLM regression indicate a cross-over in baseline Ab responses at six years old 207 (Fig. 4B). Indeed, when comparing median baseline Ab levels between disease 208 outcomes, a significant difference existed among children younger than six years of 209 age who developed asymptomatic vs. symptomatic dengue, for both SGH and 210 AeD7L1+2 (P = 0.046 and P = 0.022, respectively, Fig. 4C). Children older than six 211 years did not exhibit differences in baseline median Ab responses between disease 212 outcome groups (Fig. 4C). 213



AeD7L1+2

s

0.6

0.4 0.2

0.0

NE

2

AS

s

Dengue disease outcome

NE

AS

All rights reserved. No reuse allowed without permission.

217 Figure 4. Trends in baseline anti-Ae. aegypti IgG responses. (A) Exponentiated 218 regression coefficient estimates for the generalized linear model fitted to the IgG data per 219 assay. The circles represent the exponentiated mean coefficient estimate (the value shown above the corresponding circle). The horizontal lines represent the 95% confidence intervals 220 of the estimate. The referent group was "asymptomatic" for both disease outcome and the 221 age × disease outcome interaction term. (B) Scatterplot of standardized ELISA IgG optical 222 density (OD) values with age at study baseline, for both SGH and AeD7L1+2 (n=563). The 223 solid lines visualize the marginal effect of the age x disease outcome interaction from the 224 GLM regression fitted to the antibody data. (C) Dot and boxplots of IgG OD values for SGH 225 and AeD7L1+2, comparing different dengue disease outcomes for children younger or older 226 than six years old. The solid black horizontal line within the boxplots is the median; the lower 227 and upper borders are, respectively, the 1st and 3rd quartiles; the vertical bars indicate the 228 229 minimum and maximum values. Results of the overall Kruskal-Wallis test and the post-hoc Dunn's test for pairwise comparisons are provided. GLM = Generalized Linear Model; OD = 230 Optical Density; NE = No Event; AS = Asymptomatic dengue; S = Symptomatic dengue; 231 SGH = Salivary Gland Homogenate. Significance levels *** P<0.001; ** P<0.01; * P<0.05; ° 232 233 *P*<0.1. 234 235 3.5 Antibody reactivity to AeD7L1+2 recombinant salivary proteins is 236 specific to Aedes mosquitoes. 237 238 Since Cambodians are exposed to the bites of several hematophagous insects 239 during their life, we tested for potential cross-reactions between AeD7L1+2 proteins 240 and salivary proteins from other mosquito species abundant in our study area using 241 an inhibition immunoblot assay. We incubated SGH from Ae. albopictus, Cx. 242 quinquefasciatus, and An. dirus with a pool of Cambodian sera reactive to Ae. 243 aegypti SGH and observed recognition of several salivary proteins at diverse 244 molecular weights, including the ones respective to AeD7L1+2 (Fig 5A, left panel). 245 We then incubated the sera pool with AeD7L1+2 recombinant proteins, to absorb 246 247 AeD7L1+2 specific Abs. The sera reactivity at 28-38 kDa (corresponding to the MW of AeD7L1 and AeD7L2 proteins) was lost for both Ae. aegypti and Ae. albopictus 248 SGH (Fig 5A, right panel). However, the sera remained reactive against a Cx. 249 quinquefasciatus SGH protein of equivalent molecular weight, suggesting that 250

251 Cambodian children have anti-*Culex* Abs that do not cross-react with AeD7L1+2.

- This further supports the notion that AeD7L1+2 recombinant proteins are specific to 252
- Aedes mosquitoes. Indeed, multiple pairwise alignment of the D7L proteins from Ae. 253
- aegypti, Ae. albopictus and Cx. guinguefasciatus shows a high degree of divergence 254
- between species with few conserved areas of identity (Fig. 5B, dark shaded areas). 255
- At the Aedes genus, the AeD7L2 protein sequence is 67.85 % identical to the 256
- AlboD7L1 sequence and the AeD7L1 sequence is 71.62 % identical to the AlboD7L2 257
- sequence. Interestingly, AeD7L1 and AeD7L2 protein sequences are only 38.71 % 258
- identical. Similarly, the phylogenetic analysis of the Culicidae confirms clustering of 259
- AeD7L1 with AlboD7L2, whereas AeD7L2 sequence clustered with AlboD7L1. 260
- Proteins from both Aedes species, however, were segregated from Culex D7L or 261
- Anopheles D7L proteins. 262
- 263





264

265

Figure 5. Specificity of AeD7L1+2 recombinant proteins to Aedes mosquitoes. (A)

267 Western blots show reactivity of Cambodian sera to SGH of Ae. aegypti, Ae. albopictus, Cx.

268 *quinquefasciatus*, and *An. dirus* without (left) and with (right) pre-incubation with AeD7L1+2

269 recombinant proteins. (B) Multiple alignments of D7L proteins from Ae. aegypti, Ae.

- 270 *albopictus*, and *Cx. quinquefasciatus* using MUSCLE. The matrix indicates the percentages
- 271 of identities between D7L proteins of different species. Color shading indicate percentage
- identity between sequences, going from 100 % (black) to 0 % identity (white). The
- 273 evolutionary history was inferred using the Maximum Likelihood method. Evolutionary
- analyses were conducted in Geneious using the Paup plugin.
- 275

276 **4 Discussion**

277

Ae. aegypti SGH ELISAs are a useful tool to measure mosquito exposure (27), but 278 279 are costly, laborious, and challenging to standardize between laboratories. Here, we propose an ELISA to measure Ab responses against recombinant Ae. aegypti 280 D7L1+2 salivary proteins as a surrogate for monitoring human exposure to Ae. 281 aegypti bites. Our hypothesis relies on measuring a rapid reduction of specific IgG 282 Ab levels to AeD7L1+2 when exposure to Ae. aegypti is disrupted. Aedes aegypti 283 abundance and dengue incidence are known to fluctuate throughout seasons, as 284 has been evidenced by entomological indices and previous serosurveys (28, 29). As 285 a proof of principle, the AeD7L1+2 assay uncovered seasonal weather patterns by 286 capturing the waxing and waning of IgG Abs levels from dry to rainy season. This 287 assay This assay utilizes recombinant proteins, thereby forgoing reliance on 288 insectary maintenance and manual salivary gland dissection and enabling 289 standardization through a can be performed in a high throughput and cost-effective 290 platform and it could be assessed through a simple finger prick. It can be employed 291 to identify hot spots areas with high biting rates (30) or evaluate the effectiveness of 292 vector control methods (31-33), which could then inform allocation of scarce public 293 health resources to areas with a high risk of Aedes-borne disease transmission. 294 More so, having an accurate estimate of population exposure to Aedes mosquitoes 295 will help raise community awareness and might encourage residents in high-risk 296 areas to take protective measures (27). 297

298

The D7 subfamily of salivary proteins are widely present across the order of 299 bloodsucking Diptera (34) and likely regulate hemostasis by scavenging biogenic 300 amines and leukotrienes, which are small molecules that play essential roles in 301 302 inflammation, allergy, vascular permeability, and vascular tone (35). Indeed, salivary AeD7L knock-out mosquitoes required longer probing times than WT Ae. aegypti, 303 confirming its importance on blood feeding (36). The D7L is known to be 304 immunogenic in humans (37) and may serve as potential exposure markers for An. 305 gambiae (38). Entomological parameters estimating Ae. aegypti density are 306 associated with SGH Ab responses substantiating its use as a reference standard for 307 308 the identification of new exposure markers (9). For the first time, this study formally

correlates side-by-side paired responses to distinct Ae. aegypti salivary proteins to 309 the whole Ae. aegypti SGH. Our unbiased screening approach provides the 310 confidence that AeD7L1+2 assay is well suited to substitute Ae. aegypti SGH in 311 ELISAs. The Abs to AeD7L1+2 seem to recognize both Ae. aegypti and Ae. 312 albopictus, serving as an Aedes generic exposure tool with no detected cross-313 reactivity to Cx. guinguefasciatus or An. dirus mosquitoes SGH, a likely advantage to 314 SGH assays, where the risk of cross-reactivity may be higher. These reactivity 315 patterns are explained by the high sequence identity of D7L salivary proteins within 316 317 the Aedes genus and their high degree of divergence compared to D7L salivary proteins from *Culex* or *Anopheles* species. Deploying this *Aedes* sp. tool can be 318 advantageous for arboviral studies since both Ae. albopictus and Ae. aegypti 319 effectively transmit many of the same viruses (39, 40). In certain occasions, 320 however, specific information may be required to evaluate if the focus of 321 transmission is more urban (Ae. aegypti) or rather in forested areas (Ae. albopictus). 322

323 Our AeD7L1+2 assay could then be complemented with novel species-specific, yet 324 less sensitive, specific salivary protein ELISAs.

Using our three-year longitudinal pediatric cohort study (41), we show that IgG Ab 325 levels against AeD7L1+2 are higher in naïve children younger than six years who 326 developed asymptomatic (primary) dengue than those who developed symptomatic 327 (primary) dengue. This observation may allude to a protective effect of AeD7L Abs in 328 dengue disease outcomes. However, we were unable to replicate this association 329 when including person-time at-risk in the analysis, highlighting the complexity of this 330 "DENV – Aedes salivary proteins – anti-saliva Abs" triad. It has been shown that 331 DENV-infected individuals have significantly higher Ab titers against total Ae. aegypti 332 SGH than controls [3; 7; 12; 35]. Similarly, IgG levels against the Nterm-34 kDa and 333 AgBR1 were higher in dengue patients without warning signs than in those with 334 dengue with warning signs [10]. However, Abs against the Nterm-34kDa peptide 335 were not able to retrospectively identify individuals who developed DENV infection 336 (14) and in Colombia no statistically significant differences were found when 337 comparing antibodies to D7L between febrile DENV-negative, non-febrile DENV-338 negative or DENV-positive subjects (17), underscoring the uniqueness of each 339 salivary protein and their distinct role in disease transmission. In the mosquito 340 salivary glands, AeD7L abundance is upregulated during DENV infection and AeD7L 341

is believed to bind DENV directly forming proteins complexes (42). Interestingly, 342 AeD7L inhibited DENV infection in a human monocyte cell line and in vivo in a 343 mouse model (42). The role of AeD7L1+2 Abs in infection adds further complexity to 344 the DENV establishment in humans from endemic areas. AeD7L1+2 Abs may bind 345 to D7 during transmission and help neutralize D7-DENV complexes leading to 346 reduction in viral dissemination and primary asymptomatic dengue. However, the 347 neutralization capacity and the quality of AeD7L1+2 Abs from our dengue 348 asymptomatic versus symptomatic subjects on D7-DENV complexes remains to be 349 350 tested.

351 We acknowledge that more data are needed to validate the performance of the AeD7L1+2 assay in other populations. To expedite universal application of the 352 353 AeD7L1+2 assay we are committed to openly share the AeD7L1+2 recombinant proteins with other research groups. The AeD7L1+2 proteins used in our assay are 354 355 stable when kept refrigerated after a four-month testing period, with only a minor decay at room temperature. This supports their simple deployment in resource-356 scarce settings, especially when developed into a quantitative lateral flow assay 357 which will in turn overcome the need for expensive equipment, such as an ELISA 358 reader spectrophotometer, and inter-laboratory standardization. A limiting factor of 359 our assay is the lack of a seropositivity cutoff, which is challenging to define given 360 that most Cambodians are under constant Ae. aegypti biting pressure. Additionally, 361 we did not study other Ab isotypes or IgG subclasses but focused on IgG responses 362 given their abundance and robustness in freeze-and-thaw cycles (43-45). Future 363 mechanistic studies would benefit from in-depth investigations into the humoral and 364 cellular immune response to Ae. aegypti saliva to gain understanding of how 365 AeD7L1+2 Abs impact dengue disease outcome. Knowing the rate at which AeD7L 366 Abs decay after disrupting mosquito-human contact will be critical to optimize its use 367 as an epidemiological tool. Abs against saliva of several vector species, including 368 Ae. aegypti, are known to decline with age (11, 46-51). Yet, how these dynamics 369 impact dengue disease outcome is not well understood. Discerning these age trends 370 will be crucial when factoring them into the design of future studies. Overall, bridging 371 these gaps will contribute to a more nuanced understanding of the interplay between 372 immunity and Aedes-borne diseases and expose potential strategies for their 373 prevention and control. 374

All rights reserved. No reuse allowed without permission.

The highly sensitive and *Aedes*-specific novel AeD7L1+2 exposure assay will be useful in advancing the epidemiological understanding of *Aedes*-borne diseases. Our assay will encourage and facilitate the standardization of future serosurveys and epidemiological studies by its ability to provide a robust estimation of humanmosquito contact in a high-throughput fashion.

380

5 Material and methods

381

382 5.1 Study population and sample selection

383

The samples selected for the present study originate from the PAGODAS 384 longitudinal cohort study conducted in Cambodia, of which study protocol and results 385 are reported elsewhere (18, 41). In brief, children enrolled in the study (2-9 years 386 old) were followed up every six months for a period of three years to assess their 387 immune status against dengue and Ae. aegypti saliva. Children were considered 388 389 dengue naïve at study baseline if they were negative on the PanBio Dengue Indirect IgG enzyme-linked immunosorbent assay (ELISA), or, when ELISA positive, they 390 were negative for the presence of DENV-specific neutralizing antibodies (Abs) 391 (n=563). During the follow up period, 41 children developed symptomatic dengue as 392 confirmed by RT-PCR for DENV 1-4. Children who seroconverted via pan-DENV 393 ELISA screening with a corresponding increase in DENV 1-4 neutralization Ab titers 394 over the threshold value of 1:40 at one of the semiannual visits, and who had not 395 reported fever-like symptoms during active febrile surveillance, were considered to 396 have had asymptomatic dengue (n=173). 397 For the present study, a random sample of baseline-dengue naïve children, stratified 398 by guartiles of anti-SGH Ab response levels (i.e., high, medium, low), were selected 399 for the initial immunogenicity screening of Ae. aegypti salivary proteins by Western 400 blotting (n = 102). Ab responses against five identified salivary antigens and 401

402 combinations thereof were then measured in a random subset of samples collected

403 at all seven visits from 18 baseline-dengue naïve children (n=126) to investigate

404 correlations with the Ab response against whole SGH, and to evaluate the

seasonality of these Ab responses. Associations between anti-salivary protein Abs

406 and disease outcome (i.e., no dengue infection, symptomatic disease, or

407 asymptomatic disease) were assessed and correlations confirmed using all baseline-

All rights reserved. No reuse allowed without permission.

dengue naïve samples (n=563). Negative controls were selected from National 408 Institutes of Health (NIH) Clinical Center (CC) blood donor samples that were non-409 reactive against Ae. aegypti saliva (n = 10), positive controls were selected from 410 human sera samples with high reactivity against Ae. aegypti SGH, as defined by 411 ELISA, and stored at the International Centre of Excellence in Research laboratory. 412 413 5.2 Ethics 414 415 416 The study protocol was approved by the institutional review boards (IRB) at the US National Institutes of Health and the National Ethics Committee on Human Research 417 (NECHR) in Cambodia. The parents or guardians of all pediatric participants 418

419 provided signed informed consent to participate in the study (ClinicalTrials.gov

identifier: NCT03534245). Sera from healthy U.S. blood donors were collected

following signed informed consent from participants in the National Institutes of

422 Health Clinical Center IRB-approved protocol entitled *Collection and Distribution of*

423 Blood Components from Healthy Donors for In Vitro Research Use

- 424 (ClinicalTrials.gov identifier: NCT00001846).
- 425

426 5.3 Mosquito rearing, dissection, and salivary gland homogenization
427

Ae. aegypti (Kampong Speu strain, Cambodia and Liverpool strain, Rockville, MD), 428 Ae. albopictus (Phnom Penh strain, Cambodia), Cx. quinquefasciatus (Phnom Penh 429 strain, Cambodia), and An. dirus (Mondulkiri strain, Cambodia) mosquitoes were 430 reared in a controlled environment insectary at the National Center for Parasitology, 431 Entomology and Malaria Control (Cambodia) under a 12-h light-dark cycle, at 26° C, 432 and 75 % relative humidity. Ae. aegypti Rockefeller strain was reared under the 433 same conditions at the Laboratory of Malaria and Vector Research (National 434 Institutes of Health, U.S.). Larvae were fed with fish food (Tetra, USA) every 2 days 435 until pupae development, while adults were offered 10 % sucrose solution, ad 436 *libitum*. Salivary glands from females 7 – 10 days post-eclosion were dissected 437 under a stereomicroscope at one gland per microliter of sterile 1 x phosphate-438 buffered saline (PBS), pH 7.4 (Thermo Scientific) and stored at -80° C. Prior to use, 439 salivary glands were disrupted through ultrasonication, and supernatant collected 440 after removal of insoluble debris by centrifugation at 14,000 rpm for 5 min at 4° C. 441

All rights reserved. No reuse allowed without permission.

442

443 5.4 Production of recombinant Ae. aegypti salivary proteins

444

The human cell line HEK293 was used to recombinantly express 18 Ae. aegypti 445 recombinant proteins, as described previously (Valenzuela-Leon et al., 2022). After 446 identification of the most immunogenic proteins, we scaled up the production of 447 AeApyrase, AeD7L1, AeD7L2, NIH-23, and NIH-27 and codon-optimized them for 448 mammalian expression, synthesized with a carboxyl-terminal HIS-tag (GenScript) 449 450 and cloned into pHEK293 Ultra Expression Vectors (Takara). The SAIC Advanced Research Facility (Frederick, MD) then transfected the EXPI293F human cells and 451 recombinantly expressed the proteins. Proteins were purified from the cell culture 452 supernatant using AmMag Ni Magnetic beads (GenScript) and the AmMag Wand 453 D12 (GenScript), following manufacturer's instructions. Proteins dialysis was 454 performed overnight with sterile PBS (Lonza) using 10K MWCO Slide-A-Lyzer 455 Dialysis Cassettes (Thermo Scientific). The BCA Protein Assay Kit (Pierce) was 456 used to quantify the protein concentration, after which SDS-PAGE was performed 457 using NuPAGE Novex 4–12 % Bis-Tris gradient protein gels (Thermo Fisher 458 459 Scientific) to assess the quality of the purified proteins. Proteins were visualized with Coomassie G-250 (SimplyBlue SafeStain, Invitrogen) using the eStain protein 460

staining device (GenScript), following manufacturer's instructions.

462

463 5.5 Enzyme-linked immunosorbent assay

464

Total anti-Ae. aegypti SGH IgG was measured by performing ELISAs as adapted 465 from our previously described protocol (18). In brief, 96-well Immulon plates were 466 coated with either Ae. aegypti SGH (2 µg/ml, Kampong Speu strain) or our Ae. 467 aegypti recombinant salivary proteins (5 µg/ml) diluted in carbonate-bicarbonate 468 buffer (pH 9.6) and incubated overnight at 4° C. Plates were blocked with 200 µl of 469 TBST/BSA 4 % for 1 hour at RT and incubated with sera (diluted 1:200) for 2 hours 470 at RT. Plates were washed three times with TBST. Secondary anti-human IgG Abs 471 conjugated to alkaline phosphatase were added at a concentration of 1:10,000, 472 diluted in TBST-BSA 4 % (Millipore-Sigma A1543), and incubated for 1 hour at RT. 473 After six washes, Alkaline Phosphatase Yellow (pNPP) substrate was added, and 474 absorbance read at 450 nm within 30 minutes. Sera samples were tested in 475

All rights reserved. No reuse allowed without permission.

duplicate and retested if the coefficient of variation was above 20 %. The optical
density (OD) value of the blank control, included in each plate, was subtracted from
the raw sample OD values. The same set of positive and negative control samples
was included in each plate (per antigen) to allow for inter-plate standardization (i.e.,
OD sample / (OD positive control – OD negative control).

481

482 5.6 Western blot

483

Western blot experiments were performed to identify the most immunogenic Ae. 484 aegypti salivary proteins. In brief, 50 µg of Ae. aegypti SGH (Rockefeller strain) or 5 485 µg of recombinant proteins were denatured at 70° C for 10 minutes under non-486 reducing conditions and loaded into one 2D well (NuPAGE[™] 4 – 12 % Bis-Tris Gel, 487 Thermo Fisher Scientific) or in each lane of a 10-well gel (Bolt[™] 4 – 12 % Bis-Tris 488 489 Plus, Thermo Fisher Scientific), respectively. Proteins were separated by SDS-PAGE at 200 V for 40 min. The proteins were transferred to a 0.45 µm nitrocellulose 490 membrane (Thermo Fisher Scientific) and blocked with 5 % nonfat dried milk 491 dissolved in Tris-buffered saline with 0.05 % Tween 20 (TBST-5 % milk) (Sigma) at 492 4° C overnight. The next day, the membrane was incubated with sera samples 493 (diluted 1:200) in TBST-5 % milk. Samples were either individually loaded in the 494 mini-protean II multiscreen apparatus (Bio-Rad) (i.e., for the initial immunogenicity 495 screening of whole SGH) or pooled and transferred to hybridization bags (Kapak 496 SealPAK, ProAmpac) (i.e., to verify the immunogenicity of the five identified 497 proteins). After a 2-hour incubation at RT, the membranes were incubated for 1 hour 498 at RT with secondary alkaline phosphatase-conjugated goat anti-human IgG heavy 499 500 and light chains (IgG H+L; diluted at 1:10,000) (SIGMA). Between each phase, membranes were washed three times for five minutes with TBST. The chromogenic 501 reaction was initiated with Alkaline Phosphatase Western Blue® Stabilized Substrate 502 (Promega) and stopped with distilled water after approximately 10 to 15 minutes. 503 Images were captured using a KwikQuant Digital Western Blot Detection System 504 (Kindle Biosciences). Kindle Biosciences' KwikQuant Image Analyzer software was 505 used to analyze images and to identify reactive protein bands. For the Western blot 506 inhibition assay, we first guenched all Aedes specific antibodies by incubating the 507

All rights reserved. No reuse allowed without permission.

pooled sera with 5 µg of both recombinant AeD7L1 and AeD7L2 in hybridization
bags overnight at RT prior to incubation with the membrane.

510

511 5.7 Phylogenetic analysis

512

The sequences of the salivary D7 long form proteins from Ae. aegypti, Ae. albopictus 513 and Cx. quinquefasciatus were aligned after removal of their predicted signal peptide 514 sequence (52). Multiple sequence alignment and identity/similarity matrices were 515 constructed in Geneious v2022.1.1 using the MUSCLE algorithm (53) and the 516 PAM200 scoring matrix. Homologues of AeD7L1 and AeD7L2 were identified in the 517 Non-Redundant (NR) protein database and the Transcriptome Shotgun Assembly 518 (TSA) database using the Basic Local Alignment Search Tool (54). Mosquitoes with 519 the most homologous sequences to Ae. aegypti (based on their E-value) were 520 selected. The unrooted evolutionary tree was then constructed with PAUP 4.0 (55) 521 in Geneious v2022.1.1, following the maximum likelihood procedure of the WAG 522 amino acid substitution matrix model. The partial deletion option was applied for 523 524 gaps/missing data. The reliability of the trees was tested by the bootstrap method (n=1,000). 525

526

527 5.8 Statistical analysis

528

Normality of OD values was assessed by visual inspection of their distribution and 529 formally tested using the Shapiro-Wilk test. A Kruskal-Wallis rank test was used to 530 test for differences among > 2 groups (for non-parametric inferences), with a post-531 hoc Dunn's test. A Friedman rank test with a post-hoc Conover-Iman test was used 532 to test for differences among more than two paired groups. Multiple comparisons 533 were adjusted using the Benjamini-Hochberg procedure. The Kendall W was used 534 as a measure of the Friedman test effect size. Changes in immune responses with 535 age and disease outcome were tested by fitting generalized linear models (GLM) to 536 the Ab values, where a gamma distribution and log-link function gave the best fit by 537 log-likelihood goodness-of-fit statistics. An age and disease outcome interaction term 538 was included in the model, with age treated as a mean-centered continuous variable. 539 Correlations between anti-SGH and anti-recombinant protein IgG responses were 540 estimated by the Pearson method to investigate a linear relationship between both 541

responses (r), and by the Spearman's rank method to assess monotonic 542 relationships (r_s). Cox proportional hazards (PH) models were used to model time to 543 any dengue infection (in days), comparing those with high vs. low Ab responses at 544 baseline, and controlling for sex, age, insecticide use, larvicide use, bed net use, 545 mosquito coil use, school attendance, socio-economic status, and number of toilets 546 around the house. To fit the Cox PH models, Ab responses were categorized as high 547 or low based on a cutoff established using tertiles of Ab responses: 'high' is defined 548 as the middle and highest tertiles, 'low' as the lowest tertile. All statistical analyses 549 550 were performed in R Statistical Software (56), and graphical representations created using the 'ggplot2' and the 'corrplot' package in R (57, 58). 551 552

553 Data availability statement

554 The raw data supporting this article can be found in the supplementary files, Further 555 inquiries can be directed to the corresponding author.

556 Ethics statement

- 557 The study protocol was approved by the institutional review boards (IRB) at the US
- 558 National Institutes of Health and the National Ethics Committee on Human Research
- 559 (NECHR) in Cambodia. The parents or guardians of all pediatric participants
- 560 provided signed informed consent to participate in the study (ClinicalTrials.gov
- identifier: NCT03534245). Sera from NIH CC blood donors were collected following
- signed informed consent from participants in the National Institutes of Health Clinical
- 563 Center IRB-approved protocol entitled Collection and Distribution of Blood
- 564 Components from Healthy Donors for In Vitro Research Use (protocol number: 99-
- 565 CC-0168; ClinicalTrials.gov identifier: NCT00001846).

566 Author contributions

- 567 FO, SC, LW, JGV, JEM, CY, CL, RL, and RH conceptualized the study. SC, LW, SN,
- 568 PL, KT, JO, RSC, AP, DK, SL, RS performed experiments and discussed data.
- 569 PCVL and EC discussed data and provided reagents. FO, SC and LW performed
- 570 data analysis. FO, SC, LW wrote the manuscript. All authors contributed to the article
- and approved the submitted version.

572 Funding

- 573 This research was supported by the Intramural Research Program of the National
- 574 Institute of Allergy and Infectious Diseases at the National Institutes of Health
- 575 (Rockville, USA)

576 Acknowledgments

- 577 We thank the participating children and their parents in Chbar Mon, Kampong Speu.
- 578 We appreciate the continuous support and collaboration from the provincial health
- 579 department and hospital directors of Kampong Speu province. Additionally, we
- 580 commend the clinical staff of Kampong Speu District Referral Hospital for their
- 581 outstanding patient care in this project.

582 Conflict of interest

- 583 The authors declare that the research was conducted in the absence of any
- commercial or financial relationships that could be construed as a potential conflict ofinterest.

586

All rights reserved. No reuse allowed without permission.

587 **References**

- 588
- 589 1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, 590 Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, 591 Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-7. 592 Tian N, Zheng JX, Guo ZY, Li LH, Xia S, Lv S, Zhou XN. 2022. Dengue Incidence Trends and Its 2. 593 Burden in Major Endemic Regions from 1990 to 2019. Trop Med Infect Dis 7. 594 3. WHO. 2023. Dengue and severe dengue, on World Health Organisation. 595 https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue. Accessed 596 4. Alied M, Nguyen D, Abdul Aziz JM, Vinh DP, Huy NT. 2023. Dengue fever on the rise in 597 Southeast Asia. Pathog Glob Health 117:1-2. 598 5. Ribeiro JM. 1987. Role of saliva in blood-feeding by arthropods. Annu Rev Entomol 32:463-599 78. 600 6. Dhawan R, Kumar M, Mohanty AK, Dey G, Advani J, Prasad TS, Kumar A. 2017. Mosquito-601 Borne Diseases and Omics: Salivary Gland Proteome of the Female Aedes aegypti Mosquito. 602 OMICS 21:45-54. 603 7. Chowdhury A, Modahl CM, Misse D, Kini RM, Pompon J. 2021. High resolution proteomics of 604 Aedes aegypti salivary glands infected with either dengue, Zika or chikungunya viruses 605 identify new virus specific and broad antiviral factors. Sci Rep 11:23696. 606 8. Schneider CA, Calvo E, Peterson KE. 2021. Arboviruses: How Saliva Impacts the Journey from 607 Vector to Host. Int J Mol Sci 22. 608 9. Londono-Renteria B, Cardenas JC, Cardenas LD, Christofferson RC, Chisenhall DM, Wesson 609 DM, McCracken MK, Carvajal D, Mores CN. 2013. Use of anti-Aedes aegypti salivary extract 610 antibody concentration to correlate risk of vector exposure and dengue transmission risk in 611 Colombia. PLoS One 8:e81211. 612 10. Mathieu-Daudé F, Claverie A, Plichart C, Boulanger D, Mphande FA, Bossin HC. 2018. Specific 613 human antibody responses to Aedes aegypti and Aedes polynesiensis saliva: A new 614 epidemiological tool to assess human exposure to disease vectors in the Pacific. PLOS 615 Neglected Tropical Diseases 12. 616 11. Doucoure S, Mouchet F, Cournil A, Le Goff G, Cornelie S, Roca Y, Giraldez MG, Simon ZB, 617 Loayza R, Misse D, Flores JV, Walter A, Rogier C, Herve JP, Remoue F. 2012. Human antibody 618 response to Aedes aegypti saliva in an urban population in Bolivia: a new biomarker of 619 exposure to Dengue vector bites. Am J Trop Med Hyg 87:504-10. 620 12. Doucoure S, Mouchet F, Cornelie S, DeHecq JS, Rutee AH, Roca Y, Walter A, Herve JP, Misse 621 D, Favier F, Gasque P, Remoue F. 2012. Evaluation of the human IgG antibody response to 622 Aedes albopictus saliva as a new specific biomarker of exposure to vector bites. PLoS Negl 623 Trop Dis 6:e1487. 624 13. Doucoure S, Cornelie S, Patramool S, Mouchet F, Demettre E, Seveno M, Dehecq JS, Rutee H, 625 Herve JP, Favier F, Misse D, Gasque P, Remoue F. 2013. First screening of Aedes albopictus 626 immunogenic salivary proteins. Insect Mol Biol 22:411-23. 627 14. Ndille EE, Dubot-Peres A, Doucoure S, Mouchet F, Cornelie S, Sidavong B, Fournet F, Remoue 628 F. 2014. Human IgG antibody response to Aedes aegypti Nterm-34 kDa salivary peptide as an 629 indicator to identify areas at high risk for dengue transmission: a retrospective study in 630 urban settings of Vientiane city, Lao PDR. Trop Med Int Health 19:576-80. 15. Machain-Williams C, Mammen MP, Jr., Zeidner NS, Beaty BJ, Prenni JE, Nisalak A, Blair CD. 631 2012. Association of human immune response to Aedes aegypti salivary proteins with 632 633 dengue disease severity. Parasite Immunol 34:15-22. 634 16. Etienne V, Gallagher A, Christofferson RC, McCracken MK, Cummings DAT, Long MT. 2023. 635 Antibodies to Aedes spp. salivary proteins: a systematic review and pooled analysis. 636 Frontiers in Tropical Diseases 4.

637	17.	Londono-Renteria BL, Shakeri H, Rozo-Lopez P, Conway MJ, Duggan N, Jaberi-Douraki M,
638		Colpitts TM. 2018. Serosurvey of Human Antibodies Recognizing Aedes aegypti D7 Salivary
639		Proteins in Colombia. Front Public Health 6:111.
640	18.	Manning JE, Chea S, Parker DM, Bohl JA, Lay S, Mateja A, Man S, Nhek S, Ponce A, Sreng S,
641		Kong D, Kimsan S, Meneses C, Fay MP, Suon S, Huy R, Lon C, Leang R, Oliveira F. 2022.
642		Development of Inapparent Dengue Associated With Increased Antibody Levels to Aedes
643		aegypti Salivary Proteins: A Longitudinal Dengue Cohort in Cambodia. J Infect Dis 226:1327-
644		1337.
645	19.	Ribeiro JM, Arca B, Lombardo F, Calvo F, Phan VM, Chandra PK, Wikel SK, 2007, An
646		annotated catalogue of salivary gland transcripts in the adult female mosquito. Aedes
647		aegynti BMC Genomics 8:6
6/8	20	Valenzuela IG. Pham VM. Garfield MK. Francischetti IM. Ribeiro IM. 2002. Toward a
640	20.	description of the cialome of the adult female mesquite Addes acquisting Insect Piechem Mel
049 650		Biol 22:1101 22
650	21	DIVI 52.1101-22.
051	21.	Calvo E, Tokullasu F, Marinotti O, Villeval JL, Ribello Jivic, Francischetti IVib. 2007. Aegyptili,
652		a novel mosquito salivary giand protein, specifically binds to collagen and prevents its
653		Interaction with platelet glycoprotein VI, Integrin alpha2beta1, and Von Willebrand factor. J
654	~~	Biol Chem 282:26928-26938.
655	22.	Calvo E, Mans BJ, Andersen JF, Ribeiro JM. 2006. Function and evolution of a mosquito
656	~~	salivary protein family. J Biol Chem 281:1935-42.
657	23.	Matthews BJ, Dudchenko O, Kingan SB, Koren S, Antoshechkin I, Crawford JE, Glassford WJ,
658		Herre M, Redmond SN, Rose NH, Weedall GD, Wu Y, Batra SS, Brito-Sierra CA, Buckingham
659		SD, Campbell CL, Chan S, Cox E, Evans BR, Fansiri T, Filipovic I, Fontaine A, Gloria-Soria A, Hall
660		R, Joardar VS, Jones AK, Kay RGG, Kodali VK, Lee J, Lycett GJ, Mitchell SN, Muehling J,
661		Murphy MR, Omer AD, Partridge FA, Peluso P, Aiden AP, Ramasamy V, Rasic G, Roy S,
662		Saavedra-Rodriguez K, Sharan S, Sharma A, Smith ML, Turner J, Weakley AM, Zhao Z, Akbari
663		OS, Black WCt, Cao H, et al. 2018. Improved reference genome of Aedes aegypti informs
664		arbovirus vector control. Nature 563:501-507.
665	24.	Martins M, Ramos LFC, Murillo JR, Torres A, de Carvalho SS, Domont GB, de Oliveira DMP,
666		Mesquita RD, Nogueira FCS, Maciel-de-Freitas R, Junqueira M. 2021. Comprehensive
667		Quantitative Proteome Analysis of Aedes aegypti Identifies Proteins and Pathways Involved
668		in Wolbachia pipientis and Zika Virus Interference Phenomenon. Front Physiol 12:642237.
669	25.	Wasinpiyamongkol L, Patramool S, Luplertlop N, Surasombatpattana P, Doucoure S,
670		Mouchet F, Seveno M, Remoue F, Demettre E, Brizard JP, Jouin P, Biron DG, Thomas F, Misse
671		D. 2010. Blood-feeding and immunogenic Aedes aegypti saliva proteins. Proteomics
672		10:1906-16.
673	26.	Champagne DE, Smartt CT, Ribeiro JM, James AA, 1995. The salivary gland-specific apyrase
674	-	of the mosquito Aedes aegypti is a member of the 5'-nucleotidase family. Proc Natl Acad Sci
675		U S A 92:694-8.
676	27	Sagna AB, Kassie D, Couvray A, Adia AM, Hermann F, Riveau G, Salem G, Fournet F, Remoue
677	271	E 2019 Spatial Assessment of Contact Between Humans and Anonheles and Aedes
678		Mosquitoes in a Medium-Sized African Urban Setting Using Saliyary Antibody-Based
679		Biomarkers Infect Dis 220:1199-1208
680	28	Choi V Tang CS McIver I. Hashizume M. Chan V. Abevasinghe RR. Iddings S. Huy R. 2016
681	20.	Effects of weather factors on dengue fever incidence and implications for interventions in
682		Cambodia BMC Public Health 16:2/1
682	20	Wai KT Arunachalam N Tana S Esning E Kittavangng D Abayawickrome W Hanangama D
681	23.	Tuagi RK Htup DT Kovadup S Kroeger A Sommerfold L Detrold M 2012 Estimating density
004 695		yagi BK, Hull FT, Kuyauul S, Kiuegel A, Summerielu J, Felzulu M. 2012. Estimating dengue
605		urban and nori urban Asia. Dathog Clob Health 106:426 45
000		u ban anu pen-urban Asia. Fathog 0100 mealth 100.450-45.

30. Parker DM, Medina C, Bohl J, Lon C, Chea S, Lay S, Kong D, Nhek S, Man S, Doehl JSP, Leang R, Kry H, Rekol H, Oliveira F, Minin VM, Manning JE. 2023. Determinants of exposure to Aedes mosquitoes: A comprehensive geospatial analysis in peri-urban Cambodia. Acta Trop 239:106829. Fustec B, Phanitchat T, Aromseree S, Pientong C, Thaewnongiew K, Ekalaksananan T, 31. Cerqueira D, Poinsignon A, Elguero E, Bangs MJ, Alexander N, Overgaard HJ, Corbel V. 2021. Serological biomarker for assessing human exposure to Aedes mosquito bites during a randomized vector control intervention trial in northeastern Thailand. PLoS Negl Trop Dis 15:e0009440. Elanga Ndille E, Doucoure S, Poinsignon A, Mouchet F, Cornelie S, D'Ortenzio E, DeHecq JS, 32. Remoue F. 2016. Human IgG Antibody Response to Aedes Nterm-34kDa Salivary Peptide, an Epidemiological Tool to Assess Vector Control in Chikungunya and Dengue Transmission Area. PLoS Negl Trop Dis 10:e0005109. 33. Doucoure S, Mouchet F, Cornelie S, Drame PM, D'Ortenzio E, DeHecq JS, Remoue F. 2014. Human antibody response to Aedes albopictus salivary proteins: a potential biomarker to evaluate the efficacy of vector control in an area of Chikungunya and Dengue Virus transmission. Biomed Res Int 2014:746509. 34. Valenzuela JG, Charlab R, Gonzalez EC, de Miranda-Santos IK, Marinotti O, Francischetti IM, Ribeiro JM. 2002. The D7 family of salivary proteins in blood sucking diptera. Insect Mol Biol 11:149-55. 35. Alvarenga PH, Andersen JF. 2022. An Overview of D7 Protein Structure and Physiological Roles in Blood-Feeding Nematocera. Biology (Basel) 12. 36. Martin-Martin I, Kojin BB, Aryan A, Williams AE, Molina-Cruz A, Valenzuela-Leon PC, Shrivastava G, Botello K, Minai M, Adelman ZN, Calvo E. 2023. Aedes aegypti D7 long salivary proteins modulate blood feeding and parasite infection. mBio doi:10.1128/mbio.02289-23:e0228923.

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713 37. Oktarianti R, Senjarini K, Hayano T, Fatchiyah F, Aulanni'am. 2015. Proteomic analysis of
714 immunogenic proteins from salivary glands of Aedes aegypti. J Infect Public Health 8:575-82.

- 71538.Oseno B, Marura F, Ogwang R, Muturi M, Njunge J, Nkumama I, Mwakesi R, Mwai K, Rono716MK, Mwakubambanya R, Osier F, Tuju J. 2022. Characterization of Anopheles gambiae D7717salivary proteins as markers of human-mosquito bite contact. Parasit Vectors 15:11.
- 39. Leta S, Beyene TJ, De Clercq EM, Amenu K, Kraemer MUG, Revie CW. 2018. Global risk
 mapping for major diseases transmitted by Aedes aegypti and Aedes albopictus. Int J Infect
 Dis 67:25-35.
- 40. Kraemer MU, Sinka ME, Duda KA, Mylne AQ, Shearer FM, Barker CM, Moore CG, Carvalho
 722 RG, Coelho GE, Van Bortel W, Hendrickx G, Schaffner F, Elyazar IR, Teng HJ, Brady OJ,
 723 Messina JP, Pigott DM, Scott TW, Smith DL, Wint GR, Golding N, Hay SI. 2015. The global
 724 distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus. Elife 4:e08347.
- Manning JE, Oliveira F, Parker DM, Amaratunga C, Kong D, Man S, Sreng S, Lay S, Nang K,
 Kimsan S, Sokha L, Kamhawi S, Fay MP, Suon S, Ruhl P, Ackerman H, Huy R, Wellems TE,
 Valenzuela JG, Leang R. 2018. The PAGODAS protocol: pediatric assessment group of dengue
 and Aedes saliva protocol to investigate vector-borne determinants of Aedes-transmitted
 arboviral infections in Cambodia. Parasit Vectors 11:664.
- 42. Conway MJ, Londono-Renteria B, Troupin A, Watson AM, Klimstra WB, Fikrig E, Colpitts TM.
 2016. Aedes aegypti D7 Saliva Protein Inhibits Dengue Virus Infection. PLoS Negl Trop Dis
 10:e0004941.
- Rastawicki W, Smietanska K, Rokosz N, Jagielski M. 2012. [Effect of multiple freeze-thaw
 cycles on detection of IgA, IgG and IgM antibodies to selected bacterial antigens]. Med Dosw
 Mikrobiol 64:79-85.

736 737 738	44.	Pinsky NA, Huddleston JM, Jacobson RM, Wollan PC, Poland GA. 2003. Effect of multiple freeze-thaw cycles on detection of measles, mumps, and rubella virus antibodies. Clin Diagn
720	15	Shurrah EM, Al-Sadag DW, Amanullah E, Younes SN, Al-Jighefee H, Younes N, Dargham SP
740	45.	Vassing HM, Al Baddad LL Nasrallah GK, 2021. Effect of multiple freeze-thaw cycles on the
740 741		detection of anti-SARS-CoV-2 IgG antibodies. J Med Microbiol 70.
742	46.	Peng Z, Ho MK, Li C, Simons FE. 2004. Evidence for natural desensitization to mosquito
743		salivary allergens: mosquito saliva specific IgE and IgG levels in children. Ann Allergy Asthma
744		Immunol 93:553-6.
745	47.	Oliveira F, Traore B, Gomes R, Faye O, Gilmore DC, Keita S, Traore P, Teixeira C, Coulibaly CA,
746		Samake S, Meneses C, Sissoko I, Fairhurst RM, Fay MP, Anderson JM, Doumbia S, Kamhawi S,
747		Valenzuela JG. 2013. Delayed-type hypersensitivity to sand fly saliva in humans from a
748		leishmaniasis-endemic area of Mali is Th1-mediated and persists to midlife. J Invest
749		Dermatol 133:452-9.
750	48.	Buezo Montero S, Gabrieli P, Montarsi F, Borean A, Capelli S, De Silvestro G, Forneris F,
751		Pombi M, Breda A, Capelli G, Arca B. 2020. IgG Antibody Responses to the Aedes albopictus
752		34k2 Salivary Protein as Novel Candidate Marker of Human Exposure to the Tiger Mosquito.
753		Front Cell Infect Microbiol 10:377.
754	49.	Cardenas JC, Drame PM, Luque-Burgos KA, Berrio JD, Entrena-Mutis E, Gonzalez MU,
755		Carvajal DJ, Gutierrez-Silva LY, Cardenas LD, Colpitts TM, Mores CN, Londono-Renteria B.
756		2019. IgG1 and IgG4 antibodies against Aedes aegypti salivary proteins and risk for dengue
757		infections. PLoS One 14:e0208455.
758	50.	Montiel J, Carbal LF, Tobon-Castano A, Vasquez GM, Fisher ML, Londono-Renteria B. 2020.
759		IgG antibody response against Anopheles salivary gland proteins in asymptomatic
760		Plasmodium infections in Narino, Colombia. Malar J 19:42.
761	51.	Willen L, Milton P, Hamley JID, Walker M, Osei-Atweneboana MY, Volf P, Basanez MG,
762		Courtenay O. 2022. Demographic patterns of human antibody levels to Simulium damnosum
763		s.l. saliva in onchocerciasis-endemic areas: An indicator of exposure to vector bites. PLoS
764		Negl Trop Dis 16:e0010108.
765	52.	Almagro Armenteros JJ, Tsirigos KD, Sonderby CK, Petersen TN, Winther O, Brunak S, von
766		Heijne G, Nielsen H. 2019. SignalP 5.0 improves signal peptide predictions using deep neural
767		networks. Nat Biotechnol 37:420-423.
768	53.	Edgar RC. 2004. MUSCLE: a multiple sequence alignment method with reduced time and
769		space complexity. BMC Bioinformatics 5:113.
770	54.	Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool.
771		J Mol Biol 215:403-10.
772	55.	Wilgenbusch JC, Swofford D. 2003. Inferring evolutionary trees with PAUP*. Curr Protoc
773		Bioinformatics Chapter 6:Unit 6 4.
774	56.	R Core Team. 2023. R: A language and environment for statistical computing., vv4.3.1. R
775		Foundation for Statistical Computing, http://www.R-project.org .
776	57.	Wickham H. 2016. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York.
777	58.	Wei T, Simko V. 2021. R package 'corrplot': Visualization of a Correlation Matrix.
778		https://github.com/taiyun/corrplot. Accessed
779		
780		
781		
782		